Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 89Bio Inc (NQ: ETNB ) 8.000 -0.350 (-4.19%) Streaming Delayed Price Updated: 2:07 PM EDT, Oct 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about 89Bio Inc < Previous 1 2 3 4 5 6 7 8 9 Next > 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 October 15, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 11, 2024 From 89bio, Inc. Via GlobeNewswire 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference September 30, 2024 From 89bio, Inc. Via GlobeNewswire ETNB Stock Earnings: 89bio Beats EPS for Q2 2024 August 05, 2024 ETNB stock results show that 89bio beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 May 09, 2024 ETNB stock results show that 89bio missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 19, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer September 16, 2024 From 89bio, Inc. Via GlobeNewswire 89bio to Participate in Upcoming Investor Conferences August 29, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Appoints Francis Sarena as Chief Operating Officer August 07, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates August 05, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors August 05, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 12, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 14, 2024 From 89bio, Inc. Via GlobeNewswire What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? June 05, 2024 Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment.... Via Benzinga Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH June 05, 2024 Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease. Via Investor's Business Daily The Week Ahead: What's Next June 02, 2024 The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle. Via Talk Markets 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress May 22, 2024 -Poster presentation selected for the EASL Poster Tour, a dedicated discussion session- From 89bio, Inc. Via GlobeNewswire 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis May 14, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From 89bio, Inc. Via GlobeNewswire 89bio to Participate in the BofA Securities 2024 Health Care Conference May 08, 2024 From 89bio, Inc. Via GlobeNewswire 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH May 02, 2024 Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ET From 89bio, Inc. Via GlobeNewswire 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors April 17, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis March 27, 2024 From 89bio, Inc. Via GlobeNewswire Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? March 17, 2024 Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. Via The Motley Fool 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis March 12, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From 89bio, Inc. Via GlobeNewswire Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying March 07, 2024 Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.